Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-NaPi2b/exatecan antibody-drug conjugate TUB-040

An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), conjugated, via a cleavable linker, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-NaPi2b/exatecan ADC TUB-040, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Upon binding, cellular uptake and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and generating DNA single- and double-strand breaks. This leads to cell cycle arrest and tumor cell apoptosis. In addition, ADC TUB-040 is able to induce a bystander effect on neighboring tumor cells. This inhibits the proliferation of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.
Synonym:ADC TUB-040
anti-NaPi2b ADC TUB-040
anti-NaPi2b antibody-drug conjugate TUB-040
anti-NaPi2b/exatecan ADC TUB-040
Code name:TUB 040
TUB-040
TUB040
Search NCI's Drug Dictionary